Prevention and treatment of chronic graft-versus-host disease by mesenchymal stem cells: advances and challenges
10.3969/j.issn.1674-7445.2023.03.002
- VernacularTitle:间充质干细胞防治慢性移植物抗宿主病：进展与挑战
- Author:
Yingying BAO
1
;
Xiaoyong CHEN
Author Information
1. Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University, Guangzhou 510080, China
- Publication Type:Research Article
- Keywords:
Allogeneic hematopoietic stem cell transplantation;
Chronic graft-versus-host disease;
Mesenchymal stem cell;
Immune regulation;
B cell homeostasis;
Immune tolerance;
Fibrosis;
Biomarker
- From:
Organ Transplantation
2023;14(3):327-
- CountryChina
- Language:Chinese
-
Abstract:
Chronic graft-versus-host disease (cGVHD) is the main complication after allogeneic hematopoietic stem cell transplantation, which is also the major cause of non-relapse -related death. Due to its complex pathophysiological process, the response rate of conventional glucocorticoids combined with immunosuppressants is less than 50%. Second-line therapy should be given for patients with glucocorticoid-resistant cGVHD. Nevertheless, no consensus has been reached on current second-line therapy and the therapeutic effect is relatively poor. Mesenchymal stem cell (MSC) is one of the most common adult stem cells. Due to multi-dimensional and multi-target immune regulating function, MSC has been widely applied in the prevention and treatment of cGVHD. In addition, accumulated studies have confirmed the safety and efficacy of MSC in the treatment of cGVHD, which is expected to become a novel strategy for the prevention and management of cGVHD. In this article, research progress, mechanism and existing problems of prevention and treatment of cGVHD by MSC were reviewed, aiming to provide novel ideas for optimizing therapeutic regimens of MSC and enhancing the prevention and treatment effect of cGVHD in subsequent research.
